Chronic Inflammatory Demyelinating Polyneuropathy (Cidp) Market Share, Industry Growth and Outlook, 2016: Hexa Reports

Submitted by: Submitted by

Views: 10

Words: 824

Pages: 4

Category: Business and Industry

Date Submitted: 11/17/2016 11:19 PM

Report This Essay

Hexa Reports

Market Research Reports and Insightful Company Profiles

Chronic Inflammatory Demyelinating Polyneuropathy

(CIDP) Market Analysis, Size, Share, Industry Growth,

Insights and Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review,

H2 2016', provides an overview of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic

Inflammatory Demyelinating Polyneuropathy (CIDP), complete with analysis by stage of development,

drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Browse Detail Report With TOC @ http://hexareports.com/report/chronic-inflammatorydemyelinating-polyneuropathy-cidp-pipeline-review-h2-2016/details

The report also covers the descriptive pharmacological action of the therapeutics, its complete research

and development history and latest news and press releases. Additionally, the report provides an

overview of key players involved in therapeutic development for Chronic Inflammatory Demyelinating

Polyneuropathy (CIDP) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy

areas and nearly 3,000 indications. The report is built using data and information sourced from Global

Markets Direct's proprietary databases, company/university websites, clinical trial registries,

Hexa Reports

Market Research Reports and Insightful Company Profiles

conferences, SEC filings, investor presentations and featured press releases from company/university

sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic

review following a stringent set of processes to ensure that all the profiles are updated with the latest

set of information. Additionally, various dynamic tracking processes...